Want to see TXMD full AI Analyst Report?
TXMD Stock Chart & Stats
$2.28
<$0.01(0.49%)
At close: 4:00 PM EDT
$2.28
<$0.01(0.49%)
Day’s Range― - ―
52-Week Range$0.99 - $2.95
Previous CloseN/A
Volume8.02K
Average Volume (3M)310.58K
Market Cap
$25.70M
Enterprise Value$22.10
Total Cash (Recent Filing)$9.19M
Total Debt (Recent Filing)$5.56M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding11,574,362
10 Day Avg. Volume897,126
30 Day Avg. Volume310,579
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)0.70
Price to Sales (P/S)6.24
P/FCF Ratio7.78
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)$9.30M
Bulls Say, Bears Say
Bulls Say
Positive Free Cash FlowPositive operating and free cash flow mark a meaningful recovery from deeply negative cash generation in 2023. Sustained cash production could support ongoing royalty operations and reduce reliance on external financing, although coverage remains incomplete.
Low Financial LeverageModest leverage, positive equity and improving debt-to-equity reduce near-term solvency risk and preserve financial flexibility. This gives the company more capacity to maintain its royalty-focused model while operating profitability remains under pressure.
Lean Royalty-Focused Business ModelA royalty-focused structure can reduce the capital, sales infrastructure and execution burden associated with direct pharmaceutical commercialization. If licensed products continue generating sales, this model may provide a lower-complexity source of recurring income.
Bears Say
Small And Declining Revenue BaseThe limited and declining revenue base constrains operating leverage and leaves the company dependent on a small set of licensed products or arrangements. Continued weakness could reduce cash generation and make it harder to fund operations or develop new assets.
Negative Operating ProfitabilityMaterially negative EBIT and EBITDA show that the current revenue stream does not yet support the cost structure. Without durable improvement in royalty income or expense efficiency, positive cash flow may prove volatile and sustainable earnings remain unestablished.
Strategic Alternatives UncertaintyThe strategic review creates uncertainty around the company’s future structure, asset ownership and operating direction. An unresolved process can delay long-term planning and may produce outcomes that change the royalty vehicle without guaranteeing improved fundamentals for shareholders.
TherapeuticsMD News
TXMD FAQ
What was TherapeuticsMD’s price range in the past 12 months?
TherapeuticsMD lowest stock price was $0.99 and its highest was $2.95 in the past 12 months.
What is TherapeuticsMD’s market cap?
TherapeuticsMD’s market cap is $25.70M.
When is TherapeuticsMD’s upcoming earnings report date?
TherapeuticsMD’s upcoming earnings report date is Nov 17, 2026 which is in 80 days.
How were TherapeuticsMD’s earnings last quarter?
TherapeuticsMD released its earnings results on Aug 11, 2026. The company reported $0.013 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is TherapeuticsMD overvalued?
According to Wall Street analysts TherapeuticsMD’s price is currently Overvalued.
Does TherapeuticsMD pay dividends?
TherapeuticsMD does not currently pay dividends.
What is TherapeuticsMD’s EPS estimate?
TherapeuticsMD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TherapeuticsMD have?
TherapeuticsMD has 11,574,362 shares outstanding.
What happened to TherapeuticsMD’s price movement after its last earnings report?
TherapeuticsMD reported an EPS of $0.013 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.483%.
Which hedge fund is a major shareholder of TherapeuticsMD?
Currently, no hedge funds are holding shares in TXMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TherapeuticsMD
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Technical Analysis
Ownership Overview
1.56% Insiders
4.11% Mutual Funds
21.87% Other Institutional Investors
69.17% Public Companies and
Individual Investors